Novo Nordisk to present phase 3 FRONTIER4 interim data on hemophilia A drug denecimig at ISTH 2026

• Novo Nordisk flagged new haemophilia data scheduled for presentation at the ISTH Congress in Paris on July 11-15, 2026.
• Phase 3 FRONTIER4 analyses on investigational denecimig focus on long-term bleed prevention with flexible dosing across ages, including patients with inhibitors.
• Phase 3 explorer10 results on concizumab in children up to 11 with haemophilia A or B with inhibitors are set for first-time disclosure.
• The update reinforces a strategy to broaden its rare blood disorders portfolio with less frequent prophylaxis options, ahead of potential regulatory filings.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novo Nordisk A/S published the original content used to generate this news brief on June 26, 2026, and is solely responsible for the information contained therein.